Want to see GRCE full AI Analyst Report?
Top Page
Grace Therapeutics
(NASDAQ:GRCE)
Select Model
Select Model
Rating:49Neutral
Price Target:
$2.00
▼(-9.09% Downside)
Action:Reiterated
Date:09/19/26
The score is primarily held back by weak financial performance (no revenue, ongoing losses and cash burn) and a weak technical trend (trading below key moving averages with soft momentum). Offsetting this, recent financing that management expects to extend runway to end of 2028 provides near-term balance-sheet support, while valuation signals remain constrained by negative earnings and no dividend.
Positive Factors
Low Leverage
An effectively debt-free balance sheet limits interest obligations and reduces refinancing pressure while the company advances its pipeline. This provides greater financial flexibility than a highly leveraged development biotech, although operating losses still require careful capital management.
Negative Factors
No Revenue Base
With no reported revenue, GRCE has not yet demonstrated commercial demand or an operating engine capable of funding its activities. The business therefore remains dependent on successful product development and eventual commercialization before recurring revenue can emerge.
Read all positive and negative factors
Positive Factors
Negative Factors
Low Leverage
An effectively debt-free balance sheet limits interest obligations and reduces refinancing pressure while the company advances its pipeline. This provides greater financial flexibility than a highly leveraged development biotech, although operating losses still require careful capital management.
Read all positive factors
Grace Therapeutics (GRCE) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$44.39M
Dividend YieldN/A
Average Volume (3M)141.99K
Price to Earnings (P/E)―
Beta (1Y)1.16
Revenue GrowthN/A
EPS Growth-43.60%
CountryUS
Employees5
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-1.26
Shares Outstanding21,035,930
10 Day Avg. Volume183,442
30 Day Avg. Volume141,991
Financial Highlights & Ratios
PEG Ratio0.17
Price to Book (P/B)1.20
Price to Sales (P/S)0.00
P/FCF Ratio-8.62
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$4.00Price Target Upside81.82% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-0.68
Revenue Forecast (FY)N/A
Grace Therapeutics Business Overview & Revenue Model
Company Description
Grace Therapeutics, Inc. specializes in the creation and commercialization of pharmaceutical products, primarily targeting uncommon and neglected diseases, with operations centered in Canada. The company's most advanced experimental treatment is G...
Grace Therapeutics Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
66
Positive
Cash Flow
30
Negative
| Breakdown | TTM | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -2.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EBITDA | -25.68M | -11.07M | -23.74M | -15.37M | -24.51M | -19.17M |
| Net Income | -21.45M | -7.79M | -13.63M | -17.44M | -57.39M | -12.27M |
Balance Sheet | ||||||
| Total Assets | 50.07M | 66.65M | 71.99M | 73.30M | 79.12M | 128.62M |
| Cash, Cash Equivalents and Short-Term Investments | 13.76M | 16.98M | 22.13M | 23.00M | 27.89M | 43.66M |
| Total Debt | 0.00 | 0.00 | 0.00 | 0.00 | 485.00K | 295.00K |
| Total Liabilities | 1.86M | 2.76M | 5.38M | 11.56M | 11.17M | 20.35M |
| Stockholders Equity | 48.21M | 63.90M | 66.61M | 61.74M | 67.95M | 108.27M |
Cash Flow | ||||||
| Free Cash Flow | -10.30M | -8.87M | -14.90M | -12.36M | -15.93M | -17.23M |
| Operating Cash Flow | -10.30M | -8.87M | -14.90M | -12.33M | -15.91M | -17.23M |
| Investing Cash Flow | 0.00 | 0.00 | 0.00 | 104.00K | 13.15M | -3.52M |
| Financing Cash Flow | 4.04M | 3.71M | 14.03M | 7.36M | 304.00K | 0.00 |
Grace Therapeutics Technical Analysis
Negative
2.20
Price Trends
2.20
Negative
2.26
Negative
3.03
Negative
Market Momentum
-0.01
Positive
43.31
Neutral
13.95
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GRCE, the sentiment is Negative. The current price of 2.2 is above the 20-day moving average (MA) of 2.16, below the 50-day MA of 2.20, and below the 200-day MA of 3.03, indicating a bearish trend. The MACD of -0.01 indicates Positive momentum. The RSI at 43.31 is Neutral, neither overbought nor oversold. The STOCH value of 13.95 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for GRCE.
Grace Therapeutics Risk Analysis
Grace Therapeutics disclosed 53 risk factors in its most recent earnings report. Grace Therapeutics reported the most risks in the "Legal & Regulatory" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Grace Therapeutics Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
56 Neutral | $105.82M | -3.49 | -311.07% | ― | ― | 61.30% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | $44.39M | -1.67 | -35.78% | ― | ― | -43.60% | |
49 Neutral | $61.49M | -5.13 | 83.45% | ― | ― | 15.65% | |
45 Neutral | $3.82M | -0.22 | -406.38% | ― | ― | 44.80% | |
41 Neutral | $32.72M | -0.75 | -160.72% | ― | 893.01% | 41.74% |
* Healthcare Sector Average
GRCE
Grace Therapeutics
2.10
-1.01
-32.48%
PYPD
PolyPid
5.17
1.62
45.63%
ALGS
Aligos Therapeutics
5.49
-4.04
-42.39%
INKT
MiNK Therapeutics
12.25
-4.05
-24.85%
CVKD
Cadrenal Therapeutics, Inc.
1.09
-11.97
-91.65%
Grace Therapeutics Corporate Events
Executive/Board ChangesShareholder Meetings
Grace Therapeutics Shareholders Back Board, Pay and Auditor
Positive
Sep 18, 2026
Grace Therapeutics, Inc. held its Annual Meeting of Stockholders on September 17, 2026, with 61.28% of outstanding common shares represented, reflecting a solid level of investor participation in the company’s governance. Stockholders electe...
Business Operations and StrategyPrivate Placements and FinancingRegulatory Filings and Compliance
Grace Therapeutics Raises Capital to Advance GTx-104 Program
Positive
Aug 6, 2026
On August 4, 2026, Grace Therapeutics entered into a private placement with institutional and accredited investors to sell 4,761,904 shares of common stock at $2.10 per share, raising approximately $10 million in gross proceeds, with Craig-Hallum ...
Business Operations and StrategyProduct-Related AnnouncementsRegulatory Filings and Compliance
Grace Therapeutics advances dual-source manufacturing for GTx-104
Neutral
Jul 28, 2026
On July 28, 2026, Grace Therapeutics announced it had received formal minutes from an FDA Type A meeting held to discuss the Complete Response Letter issued on April 23, 2026 for its GTx-104 new drug application. The CRL focused on facility-level ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.